Biologics for Eosinophilic COPD: Review of Applications and Biomarkers

Qi Qi's 2026 review on figshare summarizes current applications and future prospects for biologics targeting type 2 inflammation in eosinophilic chronic obstructive pulmonary disease (COPD). The 29.9 KB document focuses on monoclonal antibodies against targets like IL-5, IL-13, and TSLP, and the role of biomarkers. It was last updated on March 18,我们发现了一个错误。

Use Cases

• Literature review on emerging biologics based on the described targets (IL-5/IL-5Rα, IL-4, IL-13, IL-33/ST-2, TSLP).
• Identify research gaps for future clinical trials based on the review of current applications and prospects.
• Inform biomarker discovery strategies for type 2 inflammation in COPD based on the document's specific focus.

Strengths

• Document is under a permissive CC-BY-4.0 license.
• Author and last update date (2026-03-18) are explicitly provided.

Limitations

• The dataset is a 29.9 KB text document, indicating a very limited scope and scale.
• Row count and column-level documentation are absent; content structure must be inferred after download.
• Description metadata is limited; actual data quality requires manual inspection after download.

Provenance

Source

figshare, author Qi Qi.

Collection Method

Likely a literature review or summary document.

Time Range

Publication date suggests content current as of 2026.

Freshness

Last updated 2026-03-18 07:45:10; freshness should be verified.

Geography

null